DIASORIN : REVISES ITS GUIDANCE UPWARDS FOR 2019 AS A CONSEQUENCE OF THE COMPLETION OF THE ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS

Press Release

DIASORIN REVISES ITS GUIDANCE UPWARDS FOR 2019 AS A CONSEQUENCE OF THE COMPLETION OF THE ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS

Saluggia (Italy), September 29, 2017 - DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA) announces the revision of its previous guidance for 2019, in view of the change in scope of consolidation following the completion of the acquisition announced today from Siemens Healthcare GmbH and affiliated companies ("Siemens Healthineers") of its micro-titre based ELISA immunodiagnostic business portfolio and related tangible and intangible assets.

The new DiaSorin's guidance for 2019, exposed at 2016 constant exchange rates, substitutes the previous guidance for the same period already released during the last Investor Day on June 26, 2017.

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD "diagnostics specialist". For more information, please visit www.diasorin.com

For additional information, please contact:

Riccardo Fava Ines Di Terlizzi

Investor Relations & Corporate Communication Senior Director Investor Relator

Tel: +39.0161.487988 Tel: +39.0161.487567

riccardo.fava@diasorin.it ines.diterlizzi@diasorin.it